Skye Bioscience is walking away from obesity entirely. The company announced on August 14, 2026, that it has signed a transaction agreement to acquire Redx Pharma Limited and simultaneously raise approximately $125 million in financing, with the combined entity rebranding as Fibrx Therapeutics and listing on Nasdaq. That pivot is sharp: as recently as May 2025, Skye was deepening its commitment to nimacimab, a peripherally restricted CB1-inhibiting antibody, through a formulation partnership with Arecor Therapeutics. Less than 15 months later, that metabolic disease bet is being replaced wholesale by a fibrosis and oncology portfolio.

The strategic logic centers on what Redx brings to the table. Redx’s pipeline includes RXC008, a GI-restricted pan-ROCK inhibitor targeting fibrostenotic Crohn’s diseaseCrohn’s disease that has completed Phase 1 and is preparing to dose its first Phase 2 patient in 2026, alongside other assets in fibrosis and oncology. For Skye, which had been running its Phase 2a CBeyond trial for nimacimab as both a monotherapy and in combination with Wegovy, the transaction represents a complete redirection of therapeutic identity, not an expansion of one. The $125 million financing is consequential here: fibrosis development is capital intensive, and a Phase 2 program in fibrostenotic Crohn’s carries meaningful execution risk given the complexity of patient selection and endpoint design in that population.

What makes this deal clinically interesting is the mismatch in program maturity. Nimacimab was mid-stream in Phase 2a obesity data generation, a point where most companies lean in rather than sell or shelve. Redx’s lead asset, by contrast, is at the Phase 1-to-2 transition, meaning Fibrx Therapeutics will spend a substantial portion of that $125 million just reaching inflection points that Skye had already partially cleared in metabolic disease. The company is effectively trading a nearer-term obesity readout for an earlier-stage fibrosis bet, presumably because the acquirer’s board judged the competitive and commercial ceiling in obesity, crowded by GLP-1 dominance, as more constraining than the scientific and regulatory risks in fibrostenotic Crohn’s.

The most concrete near-term marker to track is whether RXC008’s Phase 2 first patient dosing in fibrostenotic Crohn’s disease arrives on the timeline Redx projected before this deal closed, because any slip there would immediately test whether the $125 million financing was sized correctly for the program Fibrx Therapeutics is actually inheriting.

Source link: https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260812.htm

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.